Paul Lorigan

63.1k total citations · 4 hit papers
330 papers, 12.8k citations indexed

About

Paul Lorigan is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Paul Lorigan has authored 330 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 256 papers in Oncology, 137 papers in Molecular Biology and 56 papers in Immunology. Recurrent topics in Paul Lorigan's work include Cancer Immunotherapy and Biomarkers (95 papers), Melanoma and MAPK Pathways (83 papers) and CAR-T cell therapy research (80 papers). Paul Lorigan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (95 papers), Melanoma and MAPK Pathways (83 papers) and CAR-T cell therapy research (80 papers). Paul Lorigan collaborates with scholars based in United Kingdom, United States and Germany. Paul Lorigan's co-authors include James Larkin, Caroline Robert, Antoni Ribas, Georgina V. Long, Jean‐Jacques Grob, Fiona Blackhall, Ana Arance, Omid Hamid, Mark R. Middleton and Matteo S. Carlino and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Paul Lorigan

321 papers receiving 12.5k citations

Hit Papers

Pembrolizumab versus ipilimumab for advanced melanoma: fi... 2016 2026 2019 2022 2017 2019 2016 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
    2017 898 citations Georgina V. Long, Ana Arance et al. profile →
  2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    2019 768 citations Caroline Robert, Ana Arance et al. profile →
  3. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
  4. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
    2017 354 citations Paul Lorigan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Lorigan United Kingdom 58 9.6k 4.7k 2.6k 2.5k 2.0k 330 12.8k
Taofeek K. Owonikoko United States 52 5.8k 0.6× 3.8k 0.8× 3.4k 1.3× 1.6k 0.6× 1.3k 0.7× 326 10.7k
Lynn M. Schuchter United States 57 7.3k 0.8× 4.4k 0.9× 1.3k 0.5× 3.1k 1.2× 1.1k 0.6× 208 11.6k
Ryan J. Sullivan United States 55 9.5k 1.0× 4.0k 0.8× 2.3k 0.9× 3.3k 1.4× 1.1k 0.5× 395 13.4k
Douglas B. Johnson United States 59 9.8k 1.0× 4.6k 1.0× 2.4k 0.9× 4.0k 1.6× 970 0.5× 293 14.1k
Ulrich Keilholz Germany 65 9.2k 1.0× 6.1k 1.3× 2.2k 0.8× 5.8k 2.4× 1.0k 0.5× 477 15.5k
Mario E. Lacouture United States 67 9.5k 1.0× 3.2k 0.7× 3.1k 1.2× 1.5k 0.6× 1.8k 0.9× 375 15.1k
Svetomir N. Markovic United States 60 6.9k 0.7× 3.4k 0.7× 1.5k 0.6× 4.0k 1.6× 988 0.5× 349 12.2k
Mark R. Middleton United Kingdom 63 7.3k 0.8× 6.2k 1.3× 1.9k 0.7× 2.3k 0.9× 1.2k 0.6× 372 13.6k
Igor Puzanov United States 59 10.2k 1.1× 6.8k 1.4× 3.2k 1.2× 3.9k 1.6× 906 0.4× 302 15.5k
Richard D. Carvajal United States 54 7.2k 0.8× 4.8k 1.0× 1.9k 0.7× 3.8k 1.6× 705 0.3× 289 12.3k

Countries citing papers authored by Paul Lorigan

Since Specialization
Citations

This map shows the geographic impact of Paul Lorigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Lorigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Lorigan more than expected).

Fields of papers citing papers by Paul Lorigan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Lorigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Lorigan. The network helps show where Paul Lorigan may publish in the future.

Co-authorship network of co-authors of Paul Lorigan

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Lorigan. A scholar is included among the top collaborators of Paul Lorigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Lorigan. Paul Lorigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kennedy, Oliver, Umesh Chauhan, Louise Gorman, et al.. (2025). Cancer diagnoses, referrals, and survival in people with a learning disability in the UK: a population-based, matched cohort study. The Lancet Regional Health - Europe. 60. 101519–101519.
2.
Levell, N. J., Oliver Kennedy, Kathryn Richardson, et al.. (2025). A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021. British Journal of Dermatology. 193(6). 1146–1154.
3.
4.
Kennedy, Oliver, et al.. (2024). Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019–2023 from the English systemic anti-cancer therapy national database. SHILAP Revista de lepidopterología. 3. 100279–100279. 1 indexed citations
5.
Robert, Caroline, Caroline Dutriaux, Felix Boakye Oppong, et al.. (2024). Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).. Journal of Clinical Oncology. 42(17_suppl). LBA9503–LBA9503. 3 indexed citations
6.
Long, Georgina V., Victoria Atkinson, Paolo A. Ascierto, et al.. (2024). A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).. Journal of Clinical Oncology. 42(16_suppl). TPS9602–TPS9602. 3 indexed citations
7.
Akkooi, Alexander C. J. van, Axel Hauschild, Georgina V. Long, et al.. (2023). COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma. Future Oncology. 19(30). 2017–2027. 11 indexed citations
8.
Serra-Bellver, Patricio, Judith M. Versluis, Cong Zhou, et al.. (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European Journal of Cancer. 176. 121–132. 14 indexed citations
9.
Heywood, Richard, et al.. (2022). Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. European Journal of Cancer. 164. 62–69. 5 indexed citations
10.
Eden, Martin, Louisa G. Gordon, Tracy Epton, et al.. (2022). Cost‐effectiveness of a policy‐based intervention to reduce melanoma and other skin cancers associated with indoor tanning*. British Journal of Dermatology. 187(1). 105–114. 13 indexed citations
11.
Mandalà, Mario, Paul Lorigan, Barbara Merelli, et al.. (2021). SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. Journal for ImmunoTherapy of Cancer. 9(2). e001694–e001694. 22 indexed citations
12.
Gordon, Louisa G., Martin Eden, Tracy Epton, et al.. (2021). Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a ‘Buy-Back’ Scheme. Children. 8(5). 393–393. 7 indexed citations
13.
Reck, Martin, Alexander Luft, Aleksandra Szczęsna, et al.. (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 34(31). 3740–3748. 397 indexed citations breakdown →
14.
Hudson, Andrew, Tim Yates, Yaoyong Li, et al.. (2014). Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery. Cancer Research. 74(22). 6390–6396. 27 indexed citations
15.
Flaherty, Keith T., Reinhard Dummer, Axel Hauschild, et al.. (2013). A meta-analysis of randomized, controlled trials in metastatic melanoma establishes progression-free survival as a surrogate for overall survival. European Journal of Cancer. 1 indexed citations
16.
Girotti, María Romina, Malin Pedersen, Berta Sanchez‐Laorden, et al.. (2012). Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. Cancer Discovery. 3(2). 158–167. 272 indexed citations
17.
Lorigan, Paul, J.C. Soria, Joan Stephenson, et al.. (2010). Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc). Annals of Oncology. 21. 149–149. 6 indexed citations
18.
19.
Cesne, Axel Le, Ian Judson, John Radford, et al.. (2000). Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial. Annals of Oncology. 11. 126–126. 9 indexed citations
20.
Epurescu, Daniel, RJ Hinchliffe, Jennifer L. Peel, et al.. (1999). Total CD34 yield and CFU-GM as mobolisation and subsequent engraftment after high dose chemotherapy.. Research Explorer (The University of Manchester). 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taofeek K. Owonikoko Breakdown of academic impact, for papers by Lynn M. Schuchter Breakdown of academic impact, for papers by Ryan J. Sullivan Breakdown of academic impact, for papers by Douglas B. Johnson Breakdown of academic impact, for papers by Ulrich Keilholz Breakdown of academic impact, for papers by Mario E. Lacouture Breakdown of academic impact, for papers by Svetomir N. Markovic Breakdown of academic impact, for papers by Mark R. Middleton Breakdown of academic impact, for papers by Igor Puzanov Breakdown of academic impact, for papers by Richard D. Carvajal
Rankless by CCL
2026